Powala Christopher 4
4 · Aclaris Therapeutics, Inc. · Filed Feb 5, 2018
Insider Transaction Report
Form 4
Powala Christopher
Chief Operating Officer
Transactions
- Award
Stock option (right to buy)
2018-02-01+47,600→ 47,600 totalExercise: $22.09Exp: 2028-01-31→ Common Stock (47,600 underlying) - Award
Restricted stock units
2018-02-01+13,600→ 13,600 total→ Common Stock (13,600 underlying)
Footnotes (3)
- [F1]The option will vest over a period of four years, with 25% of the shares underlying the option vesting on the first, second, third and fourth anniversaries of the date of grant.
- [F2]Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
- [F3]The shares underlying these restricted stock units vest in four equal annual installments beginning on February 1, 2019, subject to the reporting person's continuous service with the issuer as of the applicable vesting date.